Analyze Diet

Topic:Vaccine development

Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
The pathogenic equine streptococci.
Veterinary research    July 9, 2004   Volume 35, Issue 4 397-409 doi: 10.1051/vetres:2004025
Timoney JF.Streptococci pathogenic for the horse include S. equi (S. equi subsp. equi), S. zooepidemicus (S. equi subsp. zooepidemicus), S. dysgalactiae subsp. equisimilis and S. pneumoniae capsule Type III. S. equi is a clonal descendent or biovar of an ancestral S. zooepidemicus strain with which it shares greater than 98% DNA homology and therefore expresses many of the same proteins and virulence factors. Rapid progress has been made in identification of virulence factors and proteins uniquely expressed by S. equi. Most of these are expressed either on the bacterial surface or are secreted. Notable e...
Equine Infectious Anemia Virus (EIAV): what has HIV’s country cousin got to tell us?
Veterinary research    July 9, 2004   Volume 35, Issue 4 485-512 doi: 10.1051/vetres:2004020
Leroux C, Cadoré JL, Montelaro RC.Equine Infectious Anemia Virus (EIAV) is a lentivirus, of the Retrovirus family, with an almost worldwide distribution, infecting equids. It causes a persistent infection characterized by recurring febrile episodes associating viremia, fever, thrombocytopenia, and wasting symptoms. The disease is experimentally reproducible by inoculation of Shetland ponies or horses with EIAV pathogenic strains. Among lentiviruses, EIAV is unique in that, despite a rapid virus replication and antigenic variation, most animals progress from a chronic stage characterized by recurring peaks of viremia and fever ...
DNA vaccines–back in the saddle again?
Nature biotechnology    July 2, 2004   Volume 22, Issue 7 799-801 doi: 10.1038/nbt0704-799
Powell K.A promising new horse vaccine may reignite enthusiasm for DNA vaccine technology in designing prophylactics against infectious disease. Kendall Powell reports.
[Combination immunization with EIAV Env protein expressed by recombinant baculovirus and recombinant vaccinia virus containing env gene]. Dai CM, Zhang XY, Zhang RR, Shao YM, Shen RX.To develop a novel vaccine candidate of Equine infectious anemia virus(EIAV). Methods: env genes of EIAV Chinese donkey leukocyte attenuated strain (EIAV DLV) and its parental virus strain (EIAV LN) were expressed using the BAC-To-BAC system, and Env proteins were confirmed by SDS-PAGE and Western blot. BALB/c mice were immunized with recombinant vaccinia viruses containing env genes of EIAV alone or boosted with Env proteins expressed by recombinant baculovirus. Both protective humoral and cellular immune responses were detected. Results: Recombinant baculovirus could express complete Env pro...
Recombinant Streptococcus equi proteins protect mice in challenge experiments and induce immune response in horses.
Infection and immunity    May 25, 2004   Volume 72, Issue 6 3228-3236 doi: 10.1128/IAI.72.6.3228-3236.2004
Flock M, Jacobsson K, Frykberg L, Hirst TR, Franklin A, Guss B, Flock JI.Horses that have undergone infection caused by Streptococcus equi subspecies equi (strangles) were found to have significantly increased serum antibody titers against three previously characterized proteins, FNZ (cell surface-bound fibronectin binding protein), SFS (secreted fibronectin binding protein), and EAG (alpha2-macroglobulin, albumin, and immunoglobulin G [IgG] binding protein) from S. equi. To assess the protective efficacy of vaccination with these three proteins, a mouse model of equine strangles was utilized. Parts of the three recombinant proteins were used to immunize mice, eith...
Evaluation of immune responses in horses immunized using a killed Sarcocystis neurona vaccine.
Veterinary therapeutics : research in applied veterinary medicine    May 20, 2004   Volume 5, Issue 1 34-42 
Marsh AE, Lakritz J, Johnson PJ, Miller MA, Chiang YW, Chu HJ.Clinically normal horses developed cellular immunity to Sarcocystis neurona following IM vaccination with a commercial killed S. neurona vaccine, as indicated by the development of measurable anti-S. neurona IgG antibodies and additional intradermal skin testing. Large-scale independent assessments of the vaccine's performance and safety are in progress under field conditions. The next step in the evaluation of this vaccine would be to attempt experimental challenge after a reproducible reliable equine model of S. neurona encephalitis has been established that allows for reisolation of the pat...
Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge.
Archives of virology. Supplementum    May 4, 2004   Issue 18 221-230 doi: 10.1007/978-3-7091-0572-6_20
Minke JM, Siger L, Karaca K, Austgen L, Gordy P, Bowen R, Renshaw RW, Loosmore S, Audonnet JC, Nordgren B.An ALVAC (canarypoxvirus)-based recombinant (vCP2017) expressing the prM and E genes derived from a 1999 New York isolate of West Nile virus (WNV) was constructed and assessed for its protective efficacy in horses in two different experiments. In the first trial, a dose titration study was conducted to evaluate both serum neutralising antibody responses to WNV and duration of immunity. In the second trial the onset of protection was determined. Twenty-eight adult horses received two doses of vCP2017 administered intramuscularly at 5-week intervals and sixteen horses comprised age-matched non-v...
Prospects for vaccination against equine grass sickness.
Equine veterinary journal    March 25, 2004   Volume 36, Issue 2 186-191 doi: 10.2746/0425164044868710
Hedderson EJ, Newton JR.Their is both historical and modern scientific evidence to support the hypothesis that equine grass sickness (EC'S) is caused by a toxico-infectious form of botulism involving a Clostridium botulism type C toxin 1114 is produced locally within the gastrointestinal tract of affected horses (Toc her et al. 1923: Tneher 1924: Hunter a aL 1999: Hunter and anion 2001: McCarthy 2002: McCarthy a aL 201)4a1. This report concerns a meeting convened to review the current state of knowledge and possible strategies for vaccination against EGS. including historical. clinical and pathological aspects of the...
Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination.
Veterinary immunology and immunopathology    March 11, 2004   Volume 98, Issue 3-4 127-136 doi: 10.1016/j.vetimm.2003.11.004
Breathnach CC, Rudersdorf R, Lunn DP.Recombinant modified vaccinia Ankara (MVA) vectors expressing equine influenza virus genes were constructed and evaluated for use in equine vaccination. Two strains of recombinant MVA, expressing either hemagglutinin (HA) or nucleoprotein (NP) genes were constructed. Each influenza virus gene was cloned from A/equine/Kentucky/1/81 (Eq/Ky) into an MVA construction plasmid, and was introduced to the deletion III locus of the wild type MVA genome by homologous recombination. Recombinant viruses were plaque purified, and antigen expression was confirmed by immunostaining. Two ponies were primed by...
Immunogenecity of synthetic peptides representing linear B-cell epitopes of VapA of Rhodococcus equi.
Vaccine    March 9, 2004   Volume 22, Issue 9-10 1114-1123 doi: 10.1016/j.vaccine.2003.10.006
Taouji S, Nomura I, Giguère S, Tomomitsu S, Kakuda T, Ganne V, Takaï S.Amino acid 65-78 of membrane protein VapA of the facultative intracellular Rhodococcus equi contained an immunodominant N-terminal B-cell epitope (N15Y peptide). Safety and immunogenecity of a synthetic peptide consisting of the amino acid 65-78 of VapA (peptide N15Y) were evaluated first in mice and in healthy adult horses. A single dose of a peptide-VapA vaccine induced and only in presence of adjuvant, specific IgG antibodies in sera of mice. After challenge with virulent R. equi 3 weeks after immunization, tissue clearance was more delayed in immunized mice than in control mice. An antibod...
Updating equine influenza strains in a combined equine influenza and herpesvirus vaccine.
Veterinary journal (London, England : 1997)    February 21, 2004   Volume 167, Issue 2 118-120 doi: 10.1016/S1090-0233(03)00034-0
Cullinane AA.No abstract available
Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95).
Veterinary journal (London, England : 1997)    February 21, 2004   Volume 167, Issue 2 150-157 doi: 10.1016/S1090-0233(03)00028-5
Heldens JG, Pouwels HG, van Loon AA.It has been recommended that modern equine influenza vaccines should contain an A/equi-1 strain and A/equi-2 strains of the American and European-like subtype. We describe here the efficacy of a modern updated inactivated equine influenza-herpesvirus combination vaccine against challenge with a recent American-like isolate of equine influenza (A/equine-2/Kentucky/95 (H3N8). The vaccine contains inactivated Influenza strains A-equine-1/Prague'56, A-equine-2/Newmarket-1/'93 (American lineage) and A-equine-2/ Newmarket-2/93 (Eurasian lineage) and inactivated EHV-1 strain RacH and EHV-4 strain V22...
Sarcocystis neurona-specific immunoglobulin G in the serum and cerebrospinal fluid of horses administered S neurona vaccine.
Journal of veterinary internal medicine    February 10, 2004   Volume 18, Issue 1 98-103 doi: 10.1892/0891-6640(2004)18<98:snigit>2.0.co;2
Witonsky S, Morrow JK, Leger C, Dascanio J, Buechner-Maxwell V, Palmer W, Kline K, Cook A.A vaccine against Sarcocystis neurona, which induces equine protozoal myeloencephalitis (EPM), has received conditional licensure in the United States. A major concern is whether the immunoglobulin G (IgG) response elicited by the vaccine will compromise the use of Western blotting (WB) as a diagnostic tool in vaccinated horses with neurologic disease. Our goals were to determine if vaccination (1) causes seroconversion: (2) causes at least a transient increase in S neurona-specific IgG in the cerebrospinal fluid (CSF); and (3) induces an IgG response that can be differentiated from that induc...
[Glanders–an eradicable disease–or a threat?].
Casopis lekaru ceskych    December 6, 2003   Volume 140, Issue 24 752-754 
Pospísil L.Glanders (malleus), attacking equids and transmissible to humans, does not occur in our geographical area any more, but world-wide eradication has not yet been achieved. Cases of glanders have been reported from India, Iraq, Mongolia and China and in 2001 also from South America. The disease is caused by Burkholderia mallei (earlied known as Bacillus, Pfeiferella, Loefflerella, Malleomyces, Actinobacillus, or Pseudomonas mallei). The continual interest of microbiologists in the causative agents indicates that glanders cannot be regarded as a closed historic episode. Occupational infections of ...
Oral susceptibility of South African Culicoides species to live-attenuated serotype-specific vaccine strains of African horse sickness virus (AHSV).
Medical and veterinary entomology    December 4, 2003   Volume 17, Issue 4 436-447 doi: 10.1111/j.1365-2915.2003.00467.x
Paweska JT, Prinsloo S, Venter GJ.The oral susceptibility of livestock-associated South African Culicoides midges (Diptera: Ceratopogonidae) to infection with the tissue culture-attenuated vaccine strains of African horse sickness virus (AHSV) currently in use is reported. Field-collected Culicoides were fed on horse blood-virus mixtures each containing one of the seven serotype-specific vaccine strains of AHSV, namely serotypes 1, 2, 3, 4, 6, 7 and 8. The mean titres of virus in the bloodmeals for the seven vaccine strains were between 6.8 and 7.6 log10TCID50/mL. All females (n = 3262) that survived 10 days extrinsic incubati...
Rabies DNA vaccine in the horse: strategies to improve serological responses.
Vaccine    October 25, 2003   Volume 21, Issue 31 4593-4596 doi: 10.1016/s0264-410x(03)00504-8
Fischer L, Minke J, Dufay N, Baudu P, Audonnet JC.In order for DNA vaccines to become a practical alternative to conventional vaccines their ability to induce antibody responses in large mammals needs to be improved. We used DNA vaccination against rabies in the horse as a model to test the potential of two different strategies to enhance antibody responses in a large mammalian species. The administration of the DNA vaccine in the presence of aluminum phosphate improved both the onset and the intensity of serological responses but was not potent enough to achieve seroconversion in all vaccinated ponies. However, when the DNA vaccine was formu...
Characterization of experimental equine glanders.
Microbes and infection    October 14, 2003   Volume 5, Issue 12 1125-1131 doi: 10.1016/j.micinf.2003.07.004
Lopez J, Copps J, Wilhelmsen C, Moore R, Kubay J, St-Jacques M, Halayko S, Kranendonk C, Toback S, DeShazer D, Fritz DL, Tom M, Woods DE.Considerable advances in understanding of the disease caused by Burkholderia mallei have been made employing a combination of tools including genetic techniques and animal infection models. The development of small animal models has allowed us to assess the role of a number of putative virulence determinants in the pathogenesis of disease due to B. mallei. Due to the difficulties in performing active immunization studies in small animals, and due to the fact that the horse is the target mammalian species for glanders, we have initiated experimental studies on glanders in horses. Intratracheal ...
Identification of equine herpesvirus-1 antigens recognized by cytotoxic T lymphocytes.
The Journal of general virology    September 19, 2003   Volume 84, Issue Pt 10 2625-2634 doi: 10.1099/vir.0.19268-0
Soboll G, Whalley JM, Koen MT, Allen GP, Fraser DG, Macklin MD, Swain WF, Lunn DP.Equine herpesvirus-1 (EHV-1) causes serious disease in horses throughout the world, despite the frequent use of vaccines. CTLs are thought to be critical for protection from primary and reactivating latent EHV-1 infections. However, the antigen-specificity of EHV-1-specific CTLs is unknown. The aim of this study was to identify EHV-1 genes that encode proteins containing CTL epitopes and to determine their MHC I (or ELA-A in the horse) restriction. Equine dendritic cells, transfected with a series of EHV-1 genes, were used to stimulate autologous CTL precursor populations derived from previous...
APHIS: West Nile virus vaccine safe for use.
Journal of the American Veterinary Medical Association    August 22, 2003   Volume 223, Issue 4 416-418 
Kahler SC.No abstract available
Analysis of anamnestic immune responses in adult horses and priming in neonates induced by a DNA vaccine expressing the vapA gene of Rhodococcus equi.
Vaccine    August 19, 2003   Volume 21, Issue 25-26 3815-3825 doi: 10.1016/s0264-410x(03)00329-3
Lopez AM, Hines MT, Palmer GH, Knowles DP, Alperin DC, Hines SA.Rhodococcus equi remains one of the most important pathogens of early life in horses, yet conventional vaccines to prevent rhodococcal pneumonia have not been successful. DNA vaccination offers an alternative to conventional vaccines with specific advantages for immunization of neonates. We developed a DNA vaccine expressing the vapA gene (pVR1055vapA) that induced an anamnestic response characterized by virulence associated protein A (VapA)-specific IgG antibodies in sera and bronchoalveolar lavage fluid (BALF) as well as VapA-specific proliferation of pulmonary lymphocytes when tested in adu...
Model of the equine rhinitis A virus capsid: identification of a major neutralizing immunogenic site.
The Journal of general virology    August 15, 2003   Volume 84, Issue Pt 9 2365-2373 doi: 10.1099/vir.0.19232-0
Kriegshäuser G, Wutz G, Lea S, Stuart D, Skern T, Kuechler E.Mouse monoclonal antibodies (mAbs) were employed to select neutralization escape mutants of equine rhinitis A virus (ERAV). Amino acid changes in the ERAV mutants resulting in resistance to neutralization were identified in capsid protein VP1 at Lys-114, Pro-240 and Thr-241. Although the changes were located in different parts of the polypeptide chain, these mutants exhibited cross-resistance against all four mAbs employed, indicating that these residues contribute to a single immunogenic site. To explain this result, we constructed a model of the three-dimensional structure of the ERAV capsid...
Presentation and binding affinity of equine infectious anemia virus CTL envelope and matrix protein epitopes by an expressed equine classical MHC class I molecule.
Journal of immunology (Baltimore, Md. : 1950)    August 7, 2003   Volume 171, Issue 4 1984-1993 doi: 10.4049/jimmunol.171.4.1984
McGuire TC, Leib SR, Mealey RH, Fraser DG, Prieur DJ.Control of a naturally occurring lentivirus, equine infectious anemia virus (EIAV), occurs in most infected horses and involves MHC class I-restricted, virus-specific CTL. Two minimal 12-aa epitopes, Env-RW12 and Gag-GW12, were evaluated for presentation by target cells from horses with an equine lymphocyte Ag-A1 (ELA-A1) haplotype. Fifteen of 15 presented Env-RW12 to CTL, whereas 11 of 15 presented Gag-GW12. To determine whether these epitopes were presented by different molecules, MHC class I genes were identified in cDNA clones from Arabian horse A2152, which presented both epitopes. This h...
Comparison of hamster and pony challenge models for evaluation of effect of antigenic drift on cross protection afforded by equine influenza vaccines.
Equine veterinary journal    July 24, 2003   Volume 35, Issue 5 458-462 doi: 10.2746/042516403775600433
Daly JM, Yates RJ, Browse G, Swann Z, Newton JR, Jessett D, Davis-Poynter N, Mumford JA.Vaccination and challenge studies in ponies are the most relevant experimental system for predicting whether strains included in equine influenza vaccines are relevant, but they are difficult to perform. Objective: In order to investigate the feasibility of using a small animal model, results of a cross-protection study in hamsters were compared with those from a previous pony challenge experiment. Methods: Animals were immunised with inactivated vaccines containing one of 4 strains of equine influenza A H3N8 subtype virus isolated over a 26 year period (1963 to 1989), then challenged with a 1...
[Expression and immunogenicity of equine infectious anemia virus membrane protein GP90]. Dai CB, Xiao Y, Lu H, Shen RX, Shao YM.Membrane protein GP90 of China equine infectious anemia virus (EIAV) vaccine strain (DLV) and its parental wild type LN strain were expressed with Bac-to-Bac baculovirus expression system and BALB/c mice were inoculated with purified protein, thereby to explore the availability of protein for differential diagnosis and potential for preparing genetically engineered vaccine. Methods: The authors infected donkey PBMC culture with China EIAV vaccine strain (DLV) and its parental wild type LN strain, extracted its proviral DNA as template, amplified the GP90 of DLV and LN, respectively, and expres...
Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain.
Journal of virology    July 15, 2003   Volume 77, Issue 15 8470-8480 doi: 10.1128/jvi.77.15.8470-8480.2003
Castillo-Olivares J, Wieringa R, Bakonyi T, de Vries AA, Davis-Poynter NJ, Rottier PJ.Equine arteritis virus (EAV) is an enveloped plus-strand RNA virus of the family Arteriviridae (order Nidovirales) that causes respiratory and reproductive disease in equids. Protective, virus-neutralizing antibodies (VNAb) elicited by infection are directed predominantly against an immunodominant region in the membrane-proximal domain of the viral envelope glycoprotein G(L), allowing recently the establishment of a sensitive peptide enzyme-linked immunosorbent assay (ELISA) based on this particular domain (J. Nugent et al., J. Virol. Methods 90:167-183, 2000). By using an infectious cDNA we h...
A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.
Journal of virology    June 14, 2003   Volume 77, Issue 13 7244-7253 doi: 10.1128/jvi.77.13.7244-7253.2003
Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, Issel C, Montelaro RC.Previous evaluations of inactivated whole-virus and envelope subunit vaccines to equine infectious anemia virus (EIAV) have revealed a broad spectrum of efficacy ranging from highly type-specific protection to severe enhancement of viral replication and disease in experimentally immunized equids. Among experimental animal lentivirus vaccines, immunizations with live attenuated viral strains have proven most effective, but the vaccine efficacy has been shown to be highly dependent on the nature and severity of the vaccine virus attenuation. We describe here for the first time the characterizati...
Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response.
Vaccine    June 12, 2003   Volume 21, Issue 21-22 3081-3092 doi: 10.1016/s0264-410x(03)00161-0
Soboll G, Nelson KM, Leuthner ES, Clark RJ, Drape R, Macklin MD, Swain WF, Olsen CW, Lunn DP.We have previously demonstrated that equine influenza virus hemagglutinin (HA) DNA vaccination protects ponies from challenge infection, and induces protective IgGa and IgGb responses. However, this approach does not induce a nasal IgA response. The objective of this study was to examine the value of cholera toxin (CT) administration as an adjuvant for intranasal HA DNA vaccination, and to measure protection 3 months after DNA vaccination. After an immunogenic dose of CT was determined, ponies were immunized on two occasions by intranasal administration of HA DNA and cholera toxin, or HA DNA a...
An improved Pythium insidiosum-vaccine formulation with enhanced immunotherapeutic properties in horses and dogs with pythiosis.
Vaccine    June 12, 2003   Volume 21, Issue 21-22 2797-2804 doi: 10.1016/s0264-410x(03)00225-1
Mendoza L, Mandy W, Glass R.The immunotherapeutic properties of a new Pythium insidiosum-vaccine formulation (PIV), was evaluated in 18 horses and 6 dogs with proven pythiosis from different enzootic areas in the United States. All injected horses but one responded with a weak (=29 mm, n=3), a mild (30-90 mm, n=7) or a strong (=100 mm, n=7) inflammatory reactions at the site of injection. Three equines with weak or negative reactions at the injection site were not cured. Seven equines with strong reactions at their injection sites, however, were cured. Six of the eight horses with mild reactions were also cured. The rema...
Diagnostic methods applied to analysis of an outbreak of equine influenza in a riding school in which vaccine failure occurred.
Veterinary microbiology    April 26, 2003   Volume 93, Issue 4 291-306 doi: 10.1016/s0378-1135(03)00029-4
van Maanen C, van Essen GJ, Minke J, Daly JM, Yates PJ.An outbreak of equine influenza H3N8 in a riding school is described retrospectively with emphasis on diagnosis and putative vaccine failure. In March 1995 an outbreak of equine influenza occurred among 11 horses in a riding school, where most horses had received basic primary immunizations and several booster vaccinations against influenza. Six of the 11 diseased horses had received their last booster vaccination within 5 months of the outbreak. Nevertheless, the influenza infection spread rapidly and clinical manifestations were prominent with frequent, harsh, dry coughing often accompanied ...
Efforts to pre-empt an equine influenza epidemic.
The Veterinary record    April 17, 2003   Volume 152, Issue 13 405-406 
Mumford J, Cardwell J, Daly J, Newton R.No abstract available
1 20 21 22 23 24 34